- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01556074
Evaluation of Yoga for Sleep Disturbances in Post Traumatic Stress Disorder (PTSD)
August 1, 2014 updated by: Sat Bir Khalsa, PhD, Brigham and Women's Hospital
Evaluation of Yoga for Sleep Disturbances in Insomnia and Posttraumatic Stress Disorder
The primary objective of this preliminary study is to estimate sleep outcome effect sizes and determine feasibility for a novel yoga treatment of insomnia in participants with post traumatic stress disorder (PTSD).
Additional objectives are to evaluate relationships of sleep outcomes with measures of other PTSD symptoms, psychosocial health and possible mechanisms of action.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02116
- Brigham and Women's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and non-pregnant female adults at least 18 years of age.
- A DSM-IV-TR diagnosis of post-traumatic stress disorder (PTSD).
- Naïve to yoga and other meditative practices, defined as less than one hour per week for the past 6 months.
- Potential subjects receiving ongoing medical or psychological treatment are eligible, as long as treatment remains stable over the course of the study and does not include more than one hour weekly of mind-body medicine (strategies directly related to meditation and yoga).
- No more than 2 alcoholic or caffeinated drinks/day
- No illicit drug use
- Potential subjects are eligible if they have been on stable dosage (not PRN) of medication for PTSD symptoms including sleep disturbances and any medication that may influence sleep for at least 6 weeks prior to the study, and be willing to continue with same dosage for the duration of the study.
- No current substance abuse, defined as diagnosis of substance abuse or dependence disorder within the past year, and/or in/outpatient treatment for substance abuse or dependence in the past 6 weeks.
- No transcontinental travel over the course of the study.
- No night-shift or rotating shift work over the course of the study.
- Insomnia based on the American Academy of Sleep Medicine's Research Diagnostic Criteria (RDC) for insomnia due to a mental health disorder
- Potential subjects are eligible to participate in this study if they have sufficient mental and physical ability to fully participate in the parameters of the study. Subjects must be able to understand and comply with instructions in the group yoga sessions and home practice, complete questionnaires, participate in clinical interviews, and take part in all data collection activities. Subjects with severe mental or physical concerns that may prevent them from understanding and/or complying with the treatment will be excluded. For example, potential subjects confined to wheelchairs will not be eligible, although subjects with artificial limbs who are able to reasonably participate in the intervention may be deemed eligible. These determinations will be made during discussions with potential subjects on a case by case basis during the screening process.
Exclusion Criteria:
- Potential subjects are ineligible if pregnant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Yoga treatment
|
Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in sleep quality measured by wrist actigraphy and daily sleep diaries
Time Frame: Averages of: 2-week pre-treatment baseline; last 2 weeks of treatment; 2-week long-term follow-up occuring 3-months post-treatment
|
Averages of: 2-week pre-treatment baseline; last 2 weeks of treatment; 2-week long-term follow-up occuring 3-months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Acceptability of yoga program as measured by a 2-item Yoga Evaluation Form (End) and a 2-item Yoga Evaluation Form (Followup)
Time Frame: One occurrence at 1 week following intervention, one occurrence at 3 months post-intervention
|
One occurrence at 1 week following intervention, one occurrence at 3 months post-intervention
|
Treatment adherence as measured by attendance to group yoga classes and play count monitoring of mp3's for home practice on non-class days
Time Frame: Averages over duration of intervention (8 weeks total)
|
Averages over duration of intervention (8 weeks total)
|
Accrual rate calculated from recruitment and consent information
Time Frame: Monthly for duration of recruitment period (expected to be 3 months per cohort, up to 6 to 9 months for 2 to 3 cohorts total)
|
Monthly for duration of recruitment period (expected to be 3 months per cohort, up to 6 to 9 months for 2 to 3 cohorts total)
|
Attrition rate calculated from disempanelment information
Time Frame: Monthly for duration of data collection and treatment (approximately 6 months per cohort, up to 18 months for 2 to 3 cohorts total)
|
Monthly for duration of data collection and treatment (approximately 6 months per cohort, up to 18 months for 2 to 3 cohorts total)
|
Change in PTSD symptoms as measured by the 17-item, self-reported PTSD Checklist-- Civilian version (PCL-C)
Time Frame: Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Change in 10-min segment of a seated 30-min electrocardiogram (ECG) recording
Time Frame: Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Change in emotional distress as measured by short forms of the Patient Reported Outcomes Measurement System (PROMIS) instruments for anxiety (4 items), depression (4 items) and anger (8 items)
Time Frame: Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Change in social health as measured by short forms of the Patient Reported Outcomes Measurement System (PROMIS) instruments for social functioning (4 items), social functioning satisfaction (4 items) and social isolation (6 items)
Time Frame: Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Change in interoception as measured by the 32-item self-reported Multidimensional Assessment of Interoceptive Awareness scale (MAIA)
Time Frame: Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Change in emotion regulation as measured by the Difficulties in Emotion Regulation Scale (DERS)
Time Frame: Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Change in sleep disturbance and sleep-related impairment as measured by two PROMIS scales
Time Frame: Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Once at 1-week before intervention, once at 1 week post-intervention, once at 3 months post-intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jessica J Noggle Taylor, PhD, Emory University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Actual)
February 1, 2014
Study Completion (Actual)
February 1, 2014
Study Registration Dates
First Submitted
March 8, 2012
First Submitted That Met QC Criteria
March 14, 2012
First Posted (Estimate)
March 16, 2012
Study Record Updates
Last Update Posted (Estimate)
August 4, 2014
Last Update Submitted That Met QC Criteria
August 1, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012P000263
- F32AT006092-01A1 (U.S. NIH Grant/Contract)
- 18180 (Other Grant/Funding Number: BBRF)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on Yoga treatment
-
Brigham and Women's HospitalUnited States Department of DefenseCompletedPost-Traumatic Stress DisorderUnited States
-
Robert SaperThe Cleveland ClinicCompletedBack Pain | Chronic PainUnited States
-
Centre for Addiction and Mental HealthCompleted
-
University of MalagaNot yet recruitingNervous System Diseases | Treatment Adherence | Physical Inactivity | Oculomotor; Disorder | Physical DependenceSpain
-
VA Eastern Colorado Health Care SystemCompleted
-
Children's Hospitals and Clinics of MinnesotaCompletedCystic FibrosisUnited States
-
Brown UniversityButler HospitalCompleted
-
Maria LarssonCompleted
-
Hacettepe UniversityUnknownPhysical Activity | Postural; Defect | Gender
-
Dr. Ram Manohar Lohia HospitalFogarty International Center of the National Institute of HealthCompletedSchizophrenia